id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-0918-0004,FDA,FDA-2021-N-0918,Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals,Notice,General Notice,2022-03-03T05:00:00Z,2022,3,2022-03-03T05:00:00Z,,2022-03-04T16:17:23Z,2022-04409,0,0,0900006484fb7eff
FDA-2021-N-0918-0002,FDA,FDA-2021-N-0918,"Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Labeling
Requirements for Prescription Drugs",Notice,30 Day Proposed Information Collection,2021-12-10T05:00:00Z,2021,12,2021-12-10T05:00:00Z,2022-01-11T04:59:59Z,2021-12-14T02:00:50Z,2021-26730,0,0,0900006484eb8075
FDA-2021-N-0918-0001,FDA,FDA-2021-N-0918,Agency Information Collection Activities; Proposed Collection; Comment Request; Labeling Requirements for Prescription Drugs,Notice,60 Day Proposed Information Collection,2021-09-07T04:00:00Z,2021,9,2021-09-07T04:00:00Z,2021-11-09T04:59:59Z,2021-09-07T12:56:59Z,2021-19218,0,0,0900006484d56669